1. Home
  2. GRFS vs GGAL Comparison

GRFS vs GGAL Comparison

Compare GRFS & GGAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grifols S.A.

GRFS

Grifols S.A.

HOLD

Current Price

$8.92

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Logo Grupo Financiero Galicia S.A.

GGAL

Grupo Financiero Galicia S.A.

HOLD

Current Price

$51.82

Market Cap

5.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRFS
GGAL
Founded
1940
1905
Country
Spain
Argentina
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.2B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
GRFS
GGAL
Price
$8.92
$51.82
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$10.30
$75.67
AVG Volume (30 Days)
667.0K
1.6M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.60%
1.88%
EPS Growth
N/A
N/A
EPS
0.64
0.35
Revenue
$8,821,017,248.00
$3,630,934,738.00
Revenue This Year
$5.46
$9.49
Revenue Next Year
$5.60
$13.17
P/E Ratio
$17.34
$16.24
Revenue Growth
7.31
N/A
52 Week Low
$6.19
$25.89
52 Week High
$11.14
$74.00

Technical Indicators

Market Signals
Indicator
GRFS
GGAL
Relative Strength Index (RSI) 52.15 55.26
Support Level $7.64 $50.95
Resistance Level $8.90 $53.83
Average True Range (ATR) 0.27 2.54
MACD 0.07 -0.47
Stochastic Oscillator 92.00 70.43

Price Performance

Historical Comparison
GRFS
GGAL

About GRFS Grifols S.A.

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

About GGAL Grupo Financiero Galicia S.A.

Grupo Financiero Galicia SA is a financial service holding company. It provides general banking services, proprietary brand credit card services, personal loans, insurance, and other services. The company's operating business segments are Banks, Ecosistema Naranja X, Insurance, Adjustments, and Other Businesses. It generates maximum revenue from Banks. Geographically its operate in Argentina, Uruguay, and the majority of its revenue comes from Argentina.

Share on Social Networks: